A Study of TAS-120 in Patients With Metastatic Breast Cancer

Status Active, not recruiting

Clinical Trial Summary

The purpose of the trial is to evaluate a patient's response to a Fibroblast Growth Factor Receptor (FGFR) inhibitor, futibatinib (TAS-120), used either alone or in combination with the hormonal therapy, fulvestrant. This study will be conducted in patients with metastatic breast cancer who have specific Fibroblast Growth Factor Receptor gene abnormalities and who have previously received conventional therapies to treat their breast cancer, or who are not able to tolerate certain cancer therapies. This study will also evaluate the safety of taking futibatinib, or futibatinib and fulvestrant, by learning about the potential side effects.

Clinical Trial Description

This is a Phase 2, open-label, non-randomized, multicenter study designed to evaluate the efficacy and safety of futibatinib (TAS-120) and futibatinib + fulvestrant in up to 168 adult patients with locally advanced/metastatic breast cancer harboring FGFR gene amplifications. Patients will be enrolled to 1 of 4 treatment cohorts based on diagnosis and FGFR gene amplification status, and will receive either single agent futibatinib in Cohorts 1-3 or futibatinib plus fulvestrant in Cohort 4, as follows: - Cohort 1 - HR+ HER2- Measurable Disease w/ FGFR2 Amplification - Cohort 2 - TNBC Measurable Disease w/ FGFR2 Amplification - Cohort 3 - HR+ HER2- or TNBC Non-Measurable Disease w/ FGFR2 Amplification - Cohort 4 - HR+ HER2- Measurable Disease w/ FGFR1 Amplification ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04024436
Study type	Interventional
Source	Taiho Oncology, Inc.
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	August 30, 2019
Completion date	July 5, 2024

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT04872608` - A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer	Phase 1
Terminated	`NCT02202746` - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer	Phase 2
Completed	`NCT02506556` - Phosphatidylinositol 3-kinase (PI3K) Alpha iNhibition In Advanced Breast Cancer	Phase 2
Recruiting	`NCT05534438` - A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer	Phase 2
Recruiting	`NCT03368729` - Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer	Phase 1/Phase 2
Completed	`NCT04103853` - Safety, Tolerability, and Pharmacokinetics of Proxalutamide Therapy in Women With Metastatic Breast Cancer	Phase 1
Terminated	`NCT01847599` - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib	N/A
Active, not recruiting	`NCT03147287` - Palbociclib After CDK and Endocrine Therapy (PACE)	Phase 2
Not yet recruiting	`NCT06062498` - Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer	Phase 2
Recruiting	`NCT05383196` - Onvansertib + Paclitaxel In TNBC	Phase 1/Phase 2
Recruiting	`NCT04095390` - A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer	Phase 2
Active, not recruiting	`NCT04432454` - Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation	Phase 2
Recruiting	`NCT03323346` - Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer	Phase 2
Recruiting	`NCT05744375` - Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab	Phase 2
Completed	`NCT02924883` - A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy	Phase 2
Completed	`NCT01942135` - Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)	Phase 3
Completed	`NCT01881230` - Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)	Phase 2/Phase 3
Active, not recruiting	`NCT04448886` - Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC	Phase 2
Completed	`NCT01401959` - Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy	Phase 2
Terminated	`NCT04720664` - Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer	Phase 2